A global safety evaluation of etodolac.
Etodolac has previously been reported to have an excellent safety profile. Results of recent clinical trials and of a clinical practice study were compared with the previously reported safety data for etodolac. The total incidence of patient complaints and of laboratory abnormalities continues to be low, with no apparent increase in side effects with increasing patient age. In the clinical practice study, 60% of study events occurred early in therapy (before 10 weeks). These data support an excellent safety profile for etodolac.
Karbowski
A
A
University of Münster, Federal Republic of Germany.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004008:Diclofenac / Q000009:adverse effects; D004311:Double-Blind Method; D017308:Etodolac; D005260:Female; D006801:Humans; D007210:Indoleacetic Acids / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects; D010003:Osteoarthritis / Q000188:drug therapy*; D010894:Piroxicam / Q000009:adverse effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007210:Indoleacetic Acids; D010894:Piroxicam; D004008:Diclofenac; D017308:Etodolac; D009288:Naproxen